Terms: = Skin cancer AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p AND Treatment
53 results:
1. Copper(II) Complexes with 1-(Isoquinolin-3-yl)heteroalkyl-2-ones: Synthesis, Structure and Evaluation of Anticancer, Antimicrobial and Antioxidant Potential.
Balewski Ł; Plech T; Korona-Głowniak I; Hering A; Szczesio M; Olczak A; Bednarski PJ; Kokoszka J; Kornicka A
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203181
[TBL] [Abstract] [Full Text] [Related]
2. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors.
Lewis KD; Peris K; Sekulic A; Stratigos AJ; Dunn L; Eroglu Z; Chang ALS; Migden MR; Yoo SY; Mohan K; Coates E; Okoye E; Bowler T; Baurain JF; Bechter O; Hauschild A; Butler MO; Hernandez-Aya L; Licitra L; Neves RI; Ruiz ES; Seebach F; Lowy I; Goncalves P; Fury MG
Ann Oncol; 2024 Feb; 35(2):221-228. PubMed ID: 38072158
[TBL] [Abstract] [Full Text] [Related]
3. [Relationship between PD-L1 expression and tumor stem cell marker CD44 as a promising basis for the development of new approaches to cancer targeted therapy].
Sotnikova TN; Polushkina TV; Danilova NV
Arkh Patol; 2023; 85(6):70-75. PubMed ID: 38010641
[TBL] [Abstract] [Full Text] [Related]
4. CD71
Bozorgmehr N; Okoye I; Mashhouri S; Lu J; Koleva P; Walker J; Elahi S
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37236637
[TBL] [Abstract] [Full Text] [Related]
5. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.
Park JS; Gazzaniga FS; Wu M; Luthens AK; Gillis J; Zheng W; LaFleur MW; Johnson SB; Morad G; Park EM; Zhou Y; Watowich SS; Wargo JA; Freeman GJ; Kasper DL; Sharpe AH
Nature; 2023 May; 617(7960):377-385. PubMed ID: 37138075
[TBL] [Abstract] [Full Text] [Related]
6. Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study.
Cui C; Chen Y; Luo Z; Zou Z; Jiang Y; Pan H; Fan Q; Zhao J; Xu Q; Jiang R; Wang X; Ma T; Guo Z; Si L; Chi Z; Sheng X; Dou Y; Tan Q; Wu D; Guo J
BMC Cancer; 2023 Feb; 23(1):121. PubMed ID: 36747118
[TBL] [Abstract] [Full Text] [Related]
7. Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies.
Zou Y; Yaguchi T
Exp Dermatol; 2023 Mar; 32(3):264-275. PubMed ID: 36645031
[TBL] [Abstract] [Full Text] [Related]
8. Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia.
Burgess M; Keane C; Tobin JW; Law SC; Griffin A; Gill D; Ewing AD; Atkinson V; Mollee P; Sabdia MB; Saunders NA; Gandhi MK
Acta Haematol; 2023; 146(2):166-171. PubMed ID: 36273464
[TBL] [Abstract] [Full Text] [Related]
9. CTLA4 , PD-1 , PD-L1 , PD-L2 , TIM-3 , TIGIT , and LAG3 DNA Methylation Is Associated With BAP1 -Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma.
de Vos L; Carrillo Cano TM; Zarbl R; Klümper N; Ralser DJ; Franzen A; Herr E; Gabrielpillai J; Vogt TJ; Dietrich J; Strieth S; Landsberg J; Dietrich D
J Immunother; 2022 Sep; 45(7):324-334. PubMed ID: 35862127
[TBL] [Abstract] [Full Text] [Related]
10. Lumbar Spinal Epidural Capillary Hemangioma: A Case Report and Literature Review.
Wu S; Sharma KK; Ho CL
Am J Case Rep; 2022 Jul; 23():e936181. PubMed ID: 35831983
[TBL] [Abstract] [Full Text] [Related]
11. Preclinical platforms to study therapeutic efficacy of human γδ T cells.
Ou L; Wang H; Huang H; Zhou Z; Lin Q; Guo Y; Mitchell T; Huang AC; Karakousis G; Schuchter L; Amaravadi R; Guo W; Salvino J; Herlyn M; Xu X
Clin Transl Med; 2022 Jun; 12(6):e814. PubMed ID: 35731974
[TBL] [Abstract] [Full Text] [Related]
12. Keratinocyte Carcinomas in Immunocompromised Patients Are Reduced After Administration of the Nonavalent Human Papillomavirus Vaccine.
Nichols A; Nahm W; Rabinovitz H; Ioannides T
J Drugs Dermatol; 2022 May; 21(5):526-528. PubMed ID: 35533038
[TBL] [Abstract] [Full Text] [Related]
13. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
[TBL] [Abstract] [Full Text] [Related]
14. The Fairy Chemical Imidazole-4-carboxamide Inhibits the Expression of Axl, PD-L1, and PD-L2 and Improves Response to Cisplatin in Melanoma.
Inoue C; Yasuma T; D'Alessandro-Gabazza CN; Toda M; Fridman D'Alessandro V; Inoue R; Fujimoto H; Kobori H; Tharavecharak S; Takeshita A; Nishihama K; Okano Y; Wu J; Kobayashi T; Yano Y; Kawagishi H; Gabazza EC
Cells; 2022 Jan; 11(3):. PubMed ID: 35159184
[TBL] [Abstract] [Full Text] [Related]
15. NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy.
Yoshihama S; Cho SX; Yeung J; Pan X; Lizee G; Konganti K; Johnson VE; Kobayashi KS
Sci Rep; 2021 Feb; 11(1):3258. PubMed ID: 33547395
[TBL] [Abstract] [Full Text] [Related]
16. Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation.
Saulite I; Ignatova D; Chang YT; Fassnacht C; Dimitriou F; Varypataki E; Anzengruber F; Nägeli M; Cozzio A; Dummer R; Scarisbrick J; Pascolo S; Hoetzenecker W; Bobrowicz M; Guenova E
Oncoimmunology; 2020; 9(1):1738797. PubMed ID: 32760603
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.
Hoffmann F; Zarbl R; Niebel D; Sirokay J; Fröhlich A; Posch C; Holderried TAW; Brossart P; Saavedra G; Kuster P; Strieth S; Gielen GH; Ring SS; Dietrich J; Pietsch T; Flatz L; Kristiansen G; Landsberg J; Dietrich D
Clin Epigenetics; 2020 Jun; 12(1):94. PubMed ID: 32586358
[TBL] [Abstract] [Full Text] [Related]
18. Isolated limb perfusion with melphalan activates interferon-stimulated genes to induce tumor regression in patients with melanoma in-transit metastasis.
Johansson J; Kiffin R; Aydin E; Nilsson MS; Hellstrand K; Lindnér P; Naredi P; Olofsson Bagge R; Martner A
Oncoimmunology; 2020; 9(1):1684126. PubMed ID: 32002296
[TBL] [Abstract] [Full Text] [Related]
19. The density and spatial tissue distribution of CD8
Massi D; Rulli E; Cossa M; Valeri B; Rodolfo M; Merelli B; De Logu F; Nassini R; Del Vecchio M; Di Guardo L; De Penni R; Guida M; Sileni VC; Di Giacomo AM; Tucci M; Occelli M; Portelli F; Vallacchi V; Consoli F; Quaglino P; Queirolo P; Baroni G; Carnevale-Schianca F; Cattaneo L; Minisini A; Palmieri G; Rivoltini L; Mandalà M;
J Immunother Cancer; 2019 Nov; 7(1):308. PubMed ID: 31730502
[TBL] [Abstract] [Full Text] [Related]
20. The Programmed Death Pathway in Ocular Adnexal Sebaceous Carcinoma.
Bowen RC; Lawson BM; Jody NM; Potter HD; Lucarelli MJ
Ophthalmic Plast Reconstr Surg; 2020; 36(1):74-79. PubMed ID: 31593039
[TBL] [Abstract] [Full Text] [Related]
[Next]
